cutaneous T-cell lymphoma (CTCL)

April 9, 2019

First CTCL Patients Enrolled in Phase 2 Trial of Topical Treatment WP1220

News

The Phase 2 clinical trial assessing Moleculin Biotech‘s STAT3 inhibitor, WP1220, for the topical treatment of cutaneous T-cell lymphoma (CTCL) lesions has enrolled the first two participants. The trial, to assess WP1220‘s safety and ... Read more

March 19, 2019

CTCL Patients Who Continue Treatment Use Fewer Hospital Resources, Study Says

News

Patients with cutaneous T-cell lymphoma (CTCL) who for some reason discontinue their systemic treatments require more monthly emergency room visits, hospital admissions, and longer inpatient stays than those who continue ... Read more

January 15, 2019

Volcani Center to Request Patent Coverage for Cannabis-based CTCL Therapy

News

Israel’s Volcani Center plans to submit new patent applications covering the use of a unique formulation of active compounds extracted from the cannabis plant as treatment for cutaneous T-cell lymphoma (CTCL). Further ... Read more

October 19, 2018

Soligenix Extends Enrollment in Phase 3 Trial of SGX301 in Cutaneous T-cell Lymphoma

News

The pivotal Phase 3 trial testing Soligenix‘s SGX301 will recruit an additional 40 subjects with cutaneous T-cell lymphoma — a kind of lymphoma of the skin — after a positive recommendation from an ... Read more

August 17, 2018August 17, 2018

FDA-Approved Poteligeo for Two Types of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration’s (FDA) recent approval of Poteligeo (mogamulizumab-kpkc) was based on a Phase 3 trial that showed Poteligeo significantly slowed disease progression in adults with relapsed or ... Read more

October 16, 2017October 16, 2017

Remetinostat’s Promising Results in Mycosis Fungoides Patients Presented at EORTC Meeting

News

Topical remetinostat 1% gel can significantly reduce the severity of skin lesions and itching in mycosis fungoides (MF) patients without systemic adverse events, data from a Phase 2 trial show. The ... Read more

September 21, 2017

NCI Grants $1.5M for Phase 3 Trial of SGX301 for Cutaneous T-cell Lymphoma

News

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded Soligenix a Small Business Innovation Research (SBIR) grant of nearly $1.5 million to support the company’s pivotal Phase 3 ... Read more

February 9, 2017April 17, 2017

Soligenix’s Topical Photodynamic Therapy Receives Promising Innovative Medicine Designation in UK

News

Soligenix‘s investigational photodynamic therapy, SGX301, which uses a photosensitizer activated by safe visible fluorescent light, has been designated Promising Innovative Medicine (PIM) for the treatment of cutaneous T-cell lymphoma (CTCL). The ... Read more

September 20, 2016

Lymphoma Drug, Other Soligenix Therapies to Be Presented at Investment Conference

News

Soligenix President Christopher Schaber will present a company overview at the 2016 Aegis Growth Conference Sept. 20-22 in Las Vegas, Nevada. The company is developing SGX301 (synthetic hypericin), a molecule that can be activated by ... Read more